Literature DB >> 20213105

Current and future diagnosis of hepatic encephalopathy.

Jasmohan S Bajaj1.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20213105     DOI: 10.1007/s11011-010-9176-z

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


× No keyword cloud information.
  34 in total

1.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy.

Authors:  Tarek Hassanein; Andres T Blei; William Perry; Robin Hilsabeck; Jan Stange; Fin S Larsen; Robert S Brown; Stephen Caldwell; Brendan McGuire; Frederik Nevens; Robert Fontana
Journal:  Am J Gastroenterol       Date:  2009-06       Impact factor: 10.864

3.  Neurophysiological evidence of cognitive impairment in patients without hepatic encephalopathy after transjugular intrahepatic portosystemic shunts.

Authors:  Ludwig Kramer; Edith Bauer; Alexandra Gendo; Georg Funk; Christian Madl; Johann Pidlich; Alfred Gangl
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

4.  Right hemispheric dominance of inhibitory control: an event-related functional MRI study.

Authors:  H Garavan; T J Ross; E A Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

6.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

7.  Development of a clinical hepatic encephalopathy staging scale.

Authors:  M Ortiz; J Córdoba; E Doval; C Jacas; F Pujadas; R Esteban; J Guardia
Journal:  Aliment Pharmacol Ther       Date:  2007-09-15       Impact factor: 8.171

8.  Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA).

Authors:  Tarek I Hassanein; Robin C Hilsabeck; William Perry
Journal:  Dig Dis Sci       Date:  2007-08-21       Impact factor: 3.199

9.  Utility of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) in patients with end-stage liver disease awaiting liver transplant.

Authors:  Scott Mooney; Tarek I Hasssanein; Robin C Hilsabeck; Elizabeth A Ziegler; Meghan Carlson; Leeza M Maron; William Perry
Journal:  Arch Clin Neuropsychol       Date:  2007-02-05       Impact factor: 2.813

10.  Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.

Authors:  Barjesh Chander Sharma; Praveen Sharma; Amit Agrawal; Shiv Kumar Sarin
Journal:  Gastroenterology       Date:  2009-06-06       Impact factor: 22.682

View more
  3 in total

1.  Current concepts in the pathophysiology and management of hepatic encephalopathy.

Authors:  R Todd Frederick
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-04

2.  Oridonin prevents insulin resistance-mediated cognitive disorder through PTEN/Akt pathway and autophagy in minimal hepatic encephalopathy.

Authors:  Fangfang Wen; Weishan Zhuge; Jian Wang; Xiaoai Lu; Ruimin You; Leping Liu; Qichuan Zhuge; Saidan Ding
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

3.  Mini-Mental State Examination in patients with hepatic encephalopathy and liver cirrhosis: a prospective, quantified electroencephalography study.

Authors:  Dorota Koziarska; Ewa Wunsch; Małgorzata Milkiewicz; Maciej Wójcicki; Przemysław Nowacki; Piotr Milkiewicz
Journal:  BMC Gastroenterol       Date:  2013-07-02       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.